XNASNGNE
Market cap50mUSD
Jan 08, Last price
21.49USD
1D
-1.69%
1Q
-55.37%
IPO
42.32%
Name
Neoleukin Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-11.42%
Rev. gr., 5y
%
Revenues
0k
Net income
-36m
L-34.20%
CFO
-51m
L-2.65%
Earnings
Mar 17, 2025
Profile
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 58,845 | 59,713 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (58,845) | (59,713) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (5) | |||||||
Tax Rate | ||||||||
NOPAT | (58,845) | (59,708) | ||||||
Net income | (36,317) -34.20% | (55,189) 9.25% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 92,343 | 66,532 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 2,882 | 702 | ||||||
Long-term debt | 29,628 | 8,676 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 203 | 244,366 | ||||||
Net debt | (165,155) | (72,643) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (51,422) | (52,824) | ||||||
CAPEX | (321) | (2,230) | ||||||
Cash from investing activities | 25,637 | (2,230) | ||||||
Cash from financing activities | 92,482 | 66,531 | ||||||
FCF | (55,339) | (56,638) | ||||||
| Balance | ||||||||
Cash | 197,157 | 82,021 | ||||||
Long term investments | 508 | |||||||
Excess cash | 197,665 | 82,021 | ||||||
Stockholders' equity | (187,154) | (150,592) | ||||||
Invested Capital | 389,636 | 253,908 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 12,824 | 12,824 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (55,548) | (56,513) | ||||||
EV/EBITDA | ||||||||
Interest | 12 | 2 | ||||||
Interest/NOPBT | ||||||||